Revisiting the Evidence for Dipyridamole in Reducing Restenosis : A Systematic Review and Meta-analysis
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved..
ABSTRACT: Atherosclerosis remains a leading cause of morbidity and mortality, with revascularization remaining a cornerstone of management. Conventional revascularization modalities remain challenged by target vessel reocclusion-an event driven by mechanical, thrombotic, and proliferative processes. Despite considerable advancements, restenosis remains the focus of ongoing research. Adjunctive agents, including dipyridamole, offer a multitude of effects that may improve vascular homeostasis. We sought to quantify the potential therapeutic impact of dipyridamole on vascular occlusion. We performed a literature search (EMBASE and MEDLINE) examining studies that encompassed 3 areas: (1) one of the designated medical therapies applied in (2) the setting of a vascular intervention with (3) an outcome including vascular occlusion rates and/or quantification of neointimal proliferation/restenosis. The primary outcome was vascular occlusion rates. The secondary outcome was the degree of restenosis by neointimal quantification. Both human and animal studies were included in this translational analysis. There were 6,839 articles screened, from which 73 studies were included, encompassing 16,146 vessels followed up for a mean of 327.3 days (range 7-3650 days). Preclinical studies demonstrate that dipyridamole results in reduced vascular occlusion rates {24.9% vs. 48.8%, risk ratio 0.53 [95% confidence interval (CI) 0.40-0.70], I2 = 39%, P < 0.00001}, owing to diminished neointimal proliferation [standardized mean differences -1.13 (95% CI -1.74 to -0.53), I2 = 91%, P = 0.0002]. Clinical studies similarly demonstrated reduced occlusion rates with dipyridamole therapy [23.5% vs. 31.0%, risk ratio 0.77 (95% CI 0.67-0.88), I2 = 84%, P < 0.0001]. Dipyridamole may improve post-intervention vascular patency and mitigate restenosis. Dedicated studies are warranted to delineate its role as an adjunctive agent after revascularization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Journal of cardiovascular pharmacology - 77(2021), 4 vom: 01. Apr., Seite 450-457 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Simard, Trevor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
64ALC7F90C |
|---|
| Anmerkungen: |
Date Completed 07.12.2021 Date Revised 11.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/FJC.0000000000000976 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323168175 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323168175 | ||
| 003 | DE-627 | ||
| 005 | 20231225183609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/FJC.0000000000000976 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM323168175 | ||
| 035 | |a (NLM)33760800 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Simard, Trevor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Revisiting the Evidence for Dipyridamole in Reducing Restenosis |b A Systematic Review and Meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2021 | ||
| 500 | |a Date Revised 11.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a ABSTRACT: Atherosclerosis remains a leading cause of morbidity and mortality, with revascularization remaining a cornerstone of management. Conventional revascularization modalities remain challenged by target vessel reocclusion-an event driven by mechanical, thrombotic, and proliferative processes. Despite considerable advancements, restenosis remains the focus of ongoing research. Adjunctive agents, including dipyridamole, offer a multitude of effects that may improve vascular homeostasis. We sought to quantify the potential therapeutic impact of dipyridamole on vascular occlusion. We performed a literature search (EMBASE and MEDLINE) examining studies that encompassed 3 areas: (1) one of the designated medical therapies applied in (2) the setting of a vascular intervention with (3) an outcome including vascular occlusion rates and/or quantification of neointimal proliferation/restenosis. The primary outcome was vascular occlusion rates. The secondary outcome was the degree of restenosis by neointimal quantification. Both human and animal studies were included in this translational analysis. There were 6,839 articles screened, from which 73 studies were included, encompassing 16,146 vessels followed up for a mean of 327.3 days (range 7-3650 days). Preclinical studies demonstrate that dipyridamole results in reduced vascular occlusion rates {24.9% vs. 48.8%, risk ratio 0.53 [95% confidence interval (CI) 0.40-0.70], I2 = 39%, P < 0.00001}, owing to diminished neointimal proliferation [standardized mean differences -1.13 (95% CI -1.74 to -0.53), I2 = 91%, P = 0.0002]. Clinical studies similarly demonstrated reduced occlusion rates with dipyridamole therapy [23.5% vs. 31.0%, risk ratio 0.77 (95% CI 0.67-0.88), I2 = 84%, P < 0.0001]. Dipyridamole may improve post-intervention vascular patency and mitigate restenosis. Dedicated studies are warranted to delineate its role as an adjunctive agent after revascularization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Dipyridamole |2 NLM | |
| 650 | 7 | |a 64ALC7F90C |2 NLM | |
| 700 | 1 | |a Motazedian, Pouya |e verfasserin |4 aut | |
| 700 | 1 | |a Dhaliwal, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Di Santo, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Richard G |e verfasserin |4 aut | |
| 700 | 1 | |a Ramirez, Francisco Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Labinaz, Alisha |e verfasserin |4 aut | |
| 700 | 1 | |a Short, Spencer |e verfasserin |4 aut | |
| 700 | 1 | |a Parlow, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Joseph, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Rasheed, Adil |e verfasserin |4 aut | |
| 700 | 1 | |a Rockley, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Marbach, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Domecq, Marie-Cecile |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Juan J |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Aun-Yeong |e verfasserin |4 aut | |
| 700 | 1 | |a Beanlands, Rob S |e verfasserin |4 aut | |
| 700 | 1 | |a Hibbert, Benjamin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiovascular pharmacology |d 1990 |g 77(2021), 4 vom: 01. Apr., Seite 450-457 |w (DE-627)NLM000951579 |x 1533-4023 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2021 |g number:4 |g day:01 |g month:04 |g pages:450-457 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/FJC.0000000000000976 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2021 |e 4 |b 01 |c 04 |h 450-457 | ||